Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Management estimates the majority (over 50%) of the bookings received in the first quarter will be converted to revenue over the next six-month timeframe.
Bookings were $8.6 million of which $247,000 was for extended warranties. So at least $4.3M over next 6 months.
The only way an analyst will cover Virtra is if there is banking business in the near future. This can be in the form of a future financing or some M&A deal.
That's how that business works. No analyst will cover VTSI without future business in it for the investment bank.
Minimum royalty from Modern Round for the upcoming year (Jun 2017-May 2018) will be $560,000.
Might not be very material in grand scheme of things, but remember this revenue is 100% gross margin (or close to it).
The employee profit sharing is in their most recent quarterly report.
https://www.otcmarkets.com/ajax/showFinancialReportById.pdf?id=182300
15% Profit Sharing. Virtra compensates employees with a 15% cash distribution of net profits. In nine months of 2017 this has added up to $403,709.
Is this type of compensation standard?
Date of shareholders will probably depend on if/when they complete the raise and bring in new holders. Company has mentioned in past that it will be by year end 2017. I personally expect towards end of 2017 or early 2018.
VTSI is currently meeting most of the Nasdaq listing requirements. See page 9 under Equity Standard or Net Income Standard......
https://listingcenter.nasdaq.com/assets/initialguide.pdf
Virtra still needs 300 shareholders. As of June quarter, they had 161 (see Q2 report). This is probably why they are doing a capital raise using the RegulationA rule. Increase the number of holders to 300+
Minimum $3 bid price is now also in play since they've had revenues of $6M+ in last three years.
Of course, the company still has to start filing with the SEC rather than OTC markets.
Thoughts on compensation package? In line with market or excessive?
CEO issued 10,000 options/Q
COO 7,500/Q
Each director 5,000/Q
That's about 150,000 stock options issued each year.
$SSH will be back up by mid-April, at the latest.
Company will file with FDA by March 16th. FDA has 30 days to respond. Press release disclosed all deaths were non-device related. This is just protocol. Trial will be resumed by then.
One month delay caused 25% drop in price
Makes sense. CEO Rosa has said in past that patients have opted to wait for surgery when it's absolutely necessary (Stage IV HF). This was a cause of concern when company was struggling with enrollment numbers.
Don't know how this publicity will impact future enrollments. Rational people will agree with you. However, some will associate deaths with SSH and be turned off, regardless of cause.
SSH overview of the pro's and con's from today's trial pause
http://lastfinancier.com/sunshine-heart-stock-overreacts-to-non-device-related-trial-pause/
SSH 25% does seem overblown. How do you think this will this affect future enrollments? Will it scare patients off from enrolling in trial?
ALL SSH deaths were non-device related. Plus, FDA gave interim approval just 9 days ago. They surely knew something was up yet still approved. I think 25% drop is overdone.... http://lastfinancier.com/sunshine-heart-stock-overreacts-to-non-device-related-trial-pause/
SSH tough to day trade. With momentum and some positive enrollment catalysts though, this could make for a trade into earnings in about 3 weeks
Expect SSH enrollment numbers to surprise market The company has hinted at higher enrollment through their latest loan terms:
Receive $2M upon 100 patients being enrolled in COUNTER trial no later than September 30, 2015 (“Term C Loan”)
These catalysts offer enough fuel to get it to double digits.
Later stage heart failure competitors (THOR/HTWR) are valued over 12x Sunshine Heart’s current valuation even though their target market is about 1/5th in size.
That's some serious market mis-pricing
One of the loan terms:
"Receive $2M upon 100 patients being enrolled in COUNTER trial no later than September 30, 2015 (“Term C Loan”)"
That means 60 additional patients have to be enrolled from now to September . About 20/month. Keep in mind company was only doing 13/month the last two quarters. This is why I expect price will continue uptrend with the pick up in enrollment
Bristol Myers acquired Flexus' preclinical immunotherapy asset for $1.25B. ADXS has programs for multiple indications and valued at $200M. Market mis-pricing
Company will focus on ramping up enrollment with FDA interim analysis
Expect at least 100 total enrollments by end of Q3
Sunshine Heart (SSH) expected to report interim study after FDA meeting
By end of February, SSH is announcing the results of meeting with FDA for C-Pulse interim study. This will cut the company's trial time in half as 194 patients will be needed, rather than original 388.
Company is trading in low end of 52 week range, but that could change by end of month
http://finance.yahoo.com/news/sunshine-heart-provides-corporate-103000253.html
What are your expectations within the next 6 months with regards to operation progress?
Any reason behind the steep drop? It's now trading at lows
Syngas project figure's don't add up when taking into consideration SinoCoking's financial position and potentially taking on $280M worth of debt. If they raise debt, company will pay a high interest rate, otherwise dilution is on the way.
Read why here: http://lastfinancier.com/does-sinocokings-scok-syngas-project-add-up/
King must show long term sustainable revenue streams before price is able to recover.
Growth is slowing due to Candy Crush decline. The company has the resources ($800M in cash) to recover losses through internal R&D and acquisitions. However, management is making short sighted decisions like $150M special dividend to appease shareholders from not selling come lock up expiration.
http://lastfinancier.com/king-crushed-as-growth-slows/
Evaluating the Sanofi partnership
From SNY POV, this seems like a winning deal. From MNKD, investors will need to wait on sales projections and traction of Afrezza on diabetic care market.
MannKind's primary concern was getting the best leading diabetic large pharma to market Afrezza. They did that with Sanofi, even if it means sacrificing a little on the terms. Will it be worth it in the end?
http://bit.ly/1r7pwDX
NSPH is a name to avoid until management gets their act together
No profitability in sight as management is trying to ramp top line growth. Cash is running low at these spending levels which will result in imminent dilution.
http://lastfinancier.com/investors-should-avoid-nanosphere-nsph-due-to-bleak-outlook/
Market reacted incorrectly after earnings release
Glu beat all prior expectations and posted higher guidance. Kim K revenue is expected to decline in Q4 which shouldn't be a surprise. Lower margins are the price Glu chose to pay to increase the top & bottom line. Fair trade off IMO.
http://lastfinancier.com/glu-gluu-down-after-earnings-did-market-incorrectly-react/
Interpreting ONVO KOL and agreement with Janssen
http://lastfinancier.com/interpreting-organovos-onvo-roche-kol-and-agreement-with-janssen/
VGX-3100 results not a home run but still good enough in fighting pre-cancers. More data needed to see the potential effects on cancers, which INO 3112 will provide.
http://lastfinancier.com/inovio-ino-data-not-a-home-run-but-got-company-in-great-scoring-position/
Has a potential acquisition already been priced in at these levels?
PBYI is up nearly 300% and ripe for a buyout. With Auerbach's history of selling his company to larger pharmas, has a future acquisition already been priced in PBYI or does upside still remain?
http://lastfinancier.com/puma-biotech-pbyi-up-nearly-300-after-breast-cancer-data-is-potential-acquisition-already-priced-in/
EXTR has another 20% upside remaining even after today's run
http://lastfinancier.com/extreme-networks-extr-surges-on-preliminary-results-yet-not-translating-to-bottom-line/
EXTR up 14% on day! Here's why it could reach $6 by end of summer (another 20% upside)
http://lastfinancier.com/extreme-networks-extr-surges-on-preliminary-results-yet-not-translating-to-bottom-line/
ZHNE breakout up 30%
Newly appointed CEO indicated a buyout is near. Look at his history as CEO of other companies. All acquisitions
http://lastfinancier.com/zhone-technologies-zhne-direction-with-new-ceo-ma-target/
ZHNE breakout up 30%
Newly appointed CEO indicated a buyout is near. Look at his history as CEO of other companies. All acquisitions
http://lastfinancier.com/zhone-technologies-zhne-direction-with-new-ceo-ma-target/
Zhone's direction with New CEO points to a M&A exit for investors
Look at Norrod's history. All acquisitions.
http://lastfinancier.com/zhone-technologies-zhne-direction-with-new-ceo-ma-target/
Is once weekly injection the future to diabetic therapy?
AntriaBio is taking a different approach to their treatment from other basal insulin therapies. Though still in preclinical trials, this is a hot topic with MannKind's approval. Prior early stage diabetes deals are in the hundreds of millions, offering huge upside for ANTB.
http://lastfinancier.com/antriabio-vast-upside-disruptive-once-weekly-insulin/
What to expect for Q2 earnings release
Chinese govt is making huge pushes to implement EVs and are now walking the walk also. 32M to KNDI JV. All these actions are showing quicker than expected as Kandi almost equaled 2013 EV production in Q2 alone. New model "Urban Beauty" seems to be on the way. Things looking good
http://lastfinancier.com/chinese-demand-for-electric-vehicles-lifts-kandi-kndi/
Good point on the Kardashian news being priced in already. Not sure how that can be measured but in any case, I believe the catalyst of blowing by guidance should provide more upside to the stock.
This could all be magnified if Dino Hunter can get close to the Top 10
Kim's impact and up and coming Hercules/Dino
These will cause Glu revenues to blow past estimates/ prior guidance thus in turn lead to new highs
http://lastfinancier.com/kim-kardashian-game-making-glu-mobile-gluu-a-lister/
Why you should sell after this PR spike
Low float has exaggerated the impact of this next to useless PR. There has been no topline growth to speak of. Market over reaction
http://lastfinancier.com/why-you-should-sell-digital-ally-dgly-after-pr-spike/